Core Viewpoint - WuXi AppTec's subsidiary, WuXi Biologics, reported significant growth in its mid-term performance, highlighting advancements in its cell immunotherapy products and operational efficiency [1][2] Group 1: Financial Performance - The company reported revenue of 106 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 22.5% [1] - Gross profit reached 65.12 million RMB, showing a year-on-year increase of 48.86% [1] - Research and development expenses amounted to 92.04 million RMB [1] Group 2: Product Development and Regulatory Progress - The leading product, Benauda, continues to make progress in commercialization, with successful patient enrollment for a clinical trial in second-line treatment for relapsed or refractory large B-cell lymphoma (LBCL) [2] - The National Medical Products Administration granted Benauda "Breakthrough Therapy Designation" in January 2025, and a supplemental new drug application (sNDA) was submitted in May 2025 [2] - The company has developed its own platform technology and successfully produced lentiviral vectors for Benauda manufacturing, reducing product costs while achieving comparable results to existing lentiviral vectors [2]
药明巨诺-B发布中期业绩 毛利6511.7万元 同比增加48.86%